(NMRA) Neumora Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NMRA) Neumora Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Neumora Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the actual report content, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
0 approved products
Neumora Therapeutics had 0 FDA-approved products in the portfolio at end-2025, so it had no Star in the BCG Matrix. With no marketed drug, it had no high-share, high-growth product to anchor this quadrant, and the value case stayed tied to clinical execution. Its closest asset was still prelaunch in 2025, so it was not yet a Star.
0 commercial brands
Neumora Therapeutics, Inc. remained a clinical-stage biopharma in FY2025, with no product revenue, no commercial brands, and no distribution scale. So no business unit met the BCG Star test of high market growth plus high market share. Any future Star would have to come only after FDA approval, launch, and real uptake.
0 recurring product revenue
Neumora Therapeutics disclosed no recurring product revenue from an approved portfolio, so it did not meet the usual Star profile of a product already gaining share in a growing market. The business was still pre-commercial, with cash being used mainly for R and D, not for repeat drug sales. In BCG terms, this fits a pipeline story more than a proven revenue Star.
0 market-leader franchises
Neumora Therapeutics, Inc. had 0 market-leader franchises: it had no approved product, no therapeutic-market share, and no revenue in its latest public filings. Its 2025 pipeline was still aimed at high-growth neuroscience areas, but leadership remained hypothetical because commercialization had not started. The setup was pure option value, not a Stars franchise.
- No approved products; share was zero.
- 2025 revenue remained $0.
- Pipeline was still building optionality.
- Market leadership was not yet proven.
Phase 3 lead only
Navacaprant was Neumora Therapeutics, Inc.’s most advanced asset, but it was still only in Phase 3 for major depressive disorder at end-2025. That matters: a late-stage program is not a "Star" in BCG terms until it starts selling and proving market pull. Neumora Therapeutics, Inc. still had zero product revenue, so the asset remained a development bet, not a cash engine.
- Lead asset: navacaprant
- Stage: Phase 3 only
- Indication: major depressive disorder
- Status: no commercialization yet
Neumora’s FY2025: A Pipeline Story, Not a Revenue Star
Neumora Therapeutics, Inc. had no Star in FY2025 because it ended the year with 0 approved products, $0 product revenue, and no market share in any commercial drug category. Its lead asset, navacaprant, was still Phase 3 for major depressive disorder, so the value case stayed pre-launch. In BCG terms, it was a pipeline story, not a revenue Star.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| Lead asset | navacaprant |
| Lead asset stage | Phase 3 |
What is included in the product
Detailed Word Document
Neumora’s BCG Matrix likely shows a pipeline-heavy portfolio with most assets as Question Marks and no clear Cash Cows.
Editable Excel File
One-page Neumora Therapeutics BCG Matrix easing portfolio prioritization and strategy decisions
Reference Sources
Provides a credible source trail for Neumora Therapeutics, Inc. that speeds due diligence and strengthens confidence in key assumptions.
Cash Cows
0 mature products
Neumora Therapeutics, Inc. had 0 mature, approved products and 0 commercial revenue in its pre-commercial portfolio, so it did not fit the Cash Cows profile in 2025/2026. Cash Cows need stable sales, high market share, and low-growth markets, but Neumora was still funding R&D and clinical development. With no marketed drug to generate recurring cash, the company had no Cash Cow asset to support the BCG matrix bucket.
0 profit engines
Neumora Therapeutics, Inc. had no marketed asset in 2025, so there was no steady operating profit and no cash cow to milk. Its model stayed R and D heavy, with losses driven by clinical development rather than commercial sales. That meant the business still depended on outside capital, not internal cash flow, to fund the pipeline.
0 established share
Neumora Therapeutics had no established commercial share to harvest; it was still a pre-launch biotech with no reported product revenue in its latest filings. The pipeline had not reached launch or long-term penetration, so no asset showed Cash Cow economics. Value stayed prospective, tied to clinical readouts and cash burn, not durable sales.
0 low-growth legacy brands
Neumora Therapeutics had no low-growth legacy brands to harvest in FY2025. It was still a clinical-stage biotech, with assets in clinical and preclinical development, so there was no mature product cash cow to monetize like some biopharma peers.
That means the "Cash Cows" box in the BCG Matrix was effectively empty: no older brands, no steady product revenue, and no low-growth harvesting option.
- No legacy brands
- Clinical and preclinical assets
- No cash-cow monetization
R and D funded business
Neumora Therapeutics, Inc. was not a Cash Cow; it was a cash-consuming R&D platform. In 2024, the Company reported $487.4 million in cash, cash equivalents, and marketable securities, while net loss was $273.5 million, showing balance sheet capital was funding neuroscience programs, not producing steady cash. A true Cash Cow would need an approved therapy and durable uptake.
- Cash burn, not cash generation.
- R&D funded by balance sheet capital.
- $487.4 million cash and investments.
- 2024 net loss: $273.5 million.
- Future cash cow needs approval and uptake.
Neumora’s Cash Cows Bucket Stayed Empty
Neumora Therapeutics, Inc. had no Cash Cow in FY2025 or FY2026: no approved products, no product revenue, and no stable operating cash flow. Its $487.4 million cash and investments in 2024 funded R and D, while a $273.5 million net loss showed cash burn, not harvest. So the Cash Cows bucket stayed empty.
| Metric | FY2025/FY2026 view |
|---|---|
| Approved products | 0 |
| Product revenue | 0 |
| Cash and investments | $487.4 million |
| Net loss | $273.5 million |
Full Version Awaits
Neumora Therapeutics, Inc. Reference Sources
You're previewing the exact Neumora Therapeutics, Inc. BCG Matrix file you'll receive after purchase. This is the same fully formatted document—no placeholders, no demo content, and no watermarks. Once purchased, the complete report is yours to download, use, and share right away.
Dogs
0 commercial dogs
Neumora Therapeutics had 0 approved products, so it had no commercial brands to place in the Dogs box. Dogs are low-share, low-growth assets, and Neumora had not reached that stage as of its latest 2025/2026 reporting. With no sales base, there was nothing to divest from commercial operations.
0 obsolete franchises
Neumora Therapeutics, Inc. had 0 obsolete franchises, so nothing fit the Dog box. As a clinical-stage company with no approved marketed products, it had no aging brand facing demand erosion in 2025/2026. Its value sat in new molecular entities and early pipeline assets, which were still too young for brand-level obsolescence. That left no legacy cash drain from a mature franchise.
0 trapped sales capital
Neumora Therapeutics had 0 trapped sales capital here, because it had no weak-selling commercial product to drain cash. As a clinical-stage Company, its capital sat in development programs, mainly R&D, not in a dead sales asset. That is riskier because trial spend can run before any revenue lands, but it is not a Dog profile.
0 low-share market brands
Neumora Therapeutics, Inc. had no marketed products in its portfolio, so the Dog quadrant stayed empty. All named programs were still in development, with no low-share commercial asset in a mature category and no product sales reported in its latest filings.
- No marketed product.
- Low-share commercial assets absent.
- All programs in development.
- Dog quadrant remains empty.
That means the BCG Dogs bucket does not apply to Neumora Therapeutics, Inc. at this stage. The key number is zero: zero commercial brands and zero mature-market share to classify as a Dog.
Early pipeline not dogs
Neumora Therapeutics, Inc. has no marketed drugs, so its preclinical and early clinical assets are still speculative options, not classic Dogs. The Dog quadrant is effectively empty because these programs have not yet failed as commercial products; they are still being tested for efficacy and safety. In BCG terms, the real issue is scientific risk, not terminal product decline.
That matters because the company is still funding a pipeline, not managing an aging cash cow or a stranded asset base. With no product sales to anchor the matrix, early-stage programs should be read as high-risk bets that could still move into Stars or Question Marks if data improve.
- No approved products
- Early-stage assets stay optional
- Scientific risk, not product failure
- Dog quadrant remains empty
Neumora Had No Dogs in 2025/2026
Neumora Therapeutics, Inc. had no Dogs in 2025/2026 because it reported no approved products and no commercial sales base. Its portfolio stayed in development, so there was no low-share, mature product to classify as a weak cash drain. The Dog bucket was empty.
| BCG Dog check | 2025/2026 |
|---|---|
| Approved products | 0 |
| Commercial sales base | 0 |
| Dogs | 0 |
Question Marks
Navacaprant NMRA 140 Phase 3 MDD
Navacaprant (NMRA-140) is Neumora Therapeutics, Inc.'s lead asset and its most advanced Phase 3 program in major depressive disorder, a market with tens of millions of patients and high unmet need.
Its share is still 0% because it is not approved or commercialized yet, so it brings no revenue today.
That makes it the clearest Question Mark in the BCG Matrix, and the main candidate to turn into a future Star if the Phase 3 data support approval.
NMRA 511 Phase 1 AD agitation
NMRA 511, a Phase 1 program for agitation in Alzheimer’s-related dementia, sits in a classic Question Mark spot for Neumora Therapeutics, Inc. It has zero market share today, but the addressable need is large: about 6.9 million Americans aged 65+ live with Alzheimer’s disease. If efficacy and safety hold, the franchise could move into a clinically important, commercially attractive niche.
NMRA 266 Phase 1 schizophrenia
NMRA 266 is still an early Phase 1 candidate for schizophrenia and related neuropsychiatric conditions, so it has no revenue share yet. Schizophrenia affects about 24 million people worldwide, or roughly 1 in 300 adults, and the unmet need stays high despite long-term care costs and relapse risk. Until later data de-risks it, Neumora Therapeutics, Inc. should keep it in the Question Mark box.
NMRA NMDA preclinical schizophrenia
Neumora Therapeutics, Inc. NMDA schizophrenia is a Question Mark in the BCG Matrix: it is still preclinical, so it has no sales and a 0% market share today. The upside is real if it reaches clinic and shows strong efficacy, but the failure rate in preclinical drug programs remains high. Right now, it needs capital and proof, not revenue.
- Preclinical asset, zero market share
- High optionality, high R&D risk
- Value depends on clinical entry
NMRA CK1d NLRP3 GCase preclinical
NMRA’s CK1d, NLRP3, and GCase programs are clear Question Marks: they are still preclinical, so they have no sales or market share yet, but they target large, hard neuroscience pools like ALS, neurodegeneration, and Parkinson’s disease. ALS affects about 30,000 people in the U.S., and Parkinson’s affects about 1 million, so a proof of concept win could scale fast.
- Early stage, zero commercial share
- High upside, high failure risk
- Value depends on proof of concept
Neumora’s Pipeline: Big-CNS Hope, Zero Revenue So Far
Neumora Therapeutics, Inc. question marks are all early-stage, zero-revenue bets: navacaprant in Phase 3, NMRA 511 and NMRA 266 in Phase 1, plus preclinical CK1d, NLRP3, GCase, and NMDA programs. They target large CNS markets like major depression, Alzheimer’s, schizophrenia, ALS, and Parkinson’s, but all still need proof before any market share is real.
| Program | Stage | 2026/2025 status | Market share |
|---|---|---|---|
| Navacaprant | Phase 3 | Lead asset | 0% |
| NMRA 511 | Phase 1 | Agitation in Alzheimer’s | 0% |
| NMRA 266 | Phase 1 | Schizophrenia | 0% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.